Bay Area biotech giant Bio-Rad to lay off hundreds after $1.8 billion loss
Bio-Rad Laboratories is slashing 5% of its staff, including over 100 in its Bay Area hometown, amid struggles in the biotech ...
Hosted on MSN8h
Bio-Rad set to acquire Stilla Technologies
Bio-Rad has entered a binding offer to purchase all equity interests in French biotech Stilla Technologies. According to ...
Bio-Rad Laboratories Shares Fall on 4Q Sales Miss, Cost-Cutting Plans
Bio-Rad Laboratories' cost-cutting plans come as the company swung to a loss in the fourth quarter amid lower sales across its life-science segment. The company posted a net loss of $715.8 million, or ...
Bio-Rad's Expanding Profit Margins and Stake in Sartorius Drive Long-Term Value
As of 2023 year-end, the firm had $1.2 billion of debt, $1.6 billion of cash and cash equivalents, and $1.5 billion of deferred taxes that are largely related to its Sartorius investment. We forecast ...
Bio-Rad price target lowered to $447 from $477 at RBC Capital
RBC Capital lowered the firm’s price target on Bio-Rad (BIO) to $447 from $477 and keeps an Outperform rating on the shares. The company ...